ZD6474 Phase IIa Dose Finding Multicentre Study

NCT00252746 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Carcinoma

Interventions

DRUG: ZD6474 (vandetanib) 100mg
DRUG: ZD6474 (vandetanib) 200mg
DRUG: ZD6474 (vandetanib) 300mg

Sponsor

Genzyme, a Sanofi Company